Vestmark Advisory Solutions Inc. Sells 339 Shares of Boston Scientific Co. (NYSE:BSX)

Vestmark Advisory Solutions Inc. decreased its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 0.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,977 shares of the medical equipment provider’s stock after selling 339 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Boston Scientific were worth $2,253,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of BSX. Bruce G. Allen Investments LLC purchased a new stake in shares of Boston Scientific during the 4th quarter valued at about $28,000. Motco increased its stake in Boston Scientific by 136.3% during the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 372 shares during the last quarter. Venturi Wealth Management LLC raised its position in Boston Scientific by 58.0% during the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 215 shares during the period. Asset Dedication LLC lifted its stake in shares of Boston Scientific by 42.6% in the 3rd quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 235 shares during the last quarter. Finally, CNB Bank purchased a new position in shares of Boston Scientific in the 3rd quarter worth approximately $42,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the transaction, the executive vice president now directly owns 56,508 shares in the company, valued at $3,779,820.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the sale, the executive vice president now directly owns 56,508 shares in the company, valued at $3,779,820.12. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP John Bradley Sorenson sold 16,351 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $69.30, for a total value of $1,133,124.30. Following the transaction, the executive vice president now directly owns 50,638 shares in the company, valued at $3,509,213.40. The disclosure for this sale can be found here. Insiders have sold a total of 78,384 shares of company stock valued at $5,395,560 over the last quarter. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Up 1.1 %

Shares of NYSE BSX traded up $0.82 during midday trading on Friday, reaching $72.85. 7,452,084 shares of the company’s stock traded hands, compared to its average volume of 7,241,391. The company has a market cap of $106.88 billion, a price-to-earnings ratio of 61.22, a P/E/G ratio of 2.51 and a beta of 0.77. Boston Scientific Co. has a one year low of $48.35 and a one year high of $74.39. The company has a quick ratio of 0.82, a current ratio of 1.66 and a debt-to-equity ratio of 0.47. The stock’s 50 day simple moving average is $68.42 and its 200-day simple moving average is $61.27.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. The business had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.59 billion. Boston Scientific had a return on equity of 16.39% and a net margin of 12.06%. During the same period last year, the business posted $0.45 EPS. On average, analysts predict that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on BSX. JPMorgan Chase & Co. boosted their target price on Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Boston Scientific from $63.00 to $73.00 and gave the stock a “hold” rating in a research report on Thursday, April 25th. Citigroup boosted their target price on Boston Scientific from $79.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. TD Cowen increased their price target on Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a report on Thursday, March 7th. Finally, Needham & Company LLC boosted their price objective on Boston Scientific from $71.00 to $82.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $75.09.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.